Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$1.66
EPS est.
$1.44
EPS surprise
+15.28%
1-day move
-20.12%
Insulet Corporation reported an earnings per share of $1.66, exceeding expectations by 15.28%. However, the stock reacted negatively, dropping 20.12%. This decline may be attributed to investor concerns over other undisclosed factors, as no revenue figures or management commentary were provided.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.66 | N/A | +15.28% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.
Insulet Corporation (PODD) operates in the health care sector, focusing on innovative medical devices for diabetes management, particularly their Omnipod insulin delivery system. As diabetes rates continue to rise globally, the company plays a crucial role in improving patient care and outcomes.
Last quarter
In Q1-2026, Insulet reported an EPS of $1.42, exceeding expectations by nearly 25%. Despite the positive earnings surprise, the stock fell by 9.7% the following day, indicating potential concerns among investors.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+11.63%
Avg 1-day reaction
-1.44%
Overall, expectations are mixed as Insulet prepares for its Q2-2026 earnings report. Investors are hopeful for continued growth but cautious due to the recent stock price decline.
Bull case
If Insulet can demonstrate strong customer growth and maintain or improve EPS, it could signal robust demand for its products, leading to a positive market reaction.
Bear case
Conversely, any signs of slowing growth or disappointing customer acquisition could lead to further declines in stock price, especially given the recent volatility.
The print will turn on these.
Q1
What is the growth rate of new customers using the Omnipod system?
This metric will indicate the company's ability to capture market share and drive future revenue.
Q2
How does Insulet plan to address any potential supply chain challenges?
Supply chain issues could impact product availability and sales, making this a critical area of focus for investors.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The market may be underestimating Insulet's ability to innovate and capture new customers, especially in light of recent product enhancements.
Supporting evidence
The recent EPS beat indicates strong underlying performance despite stock price volatility.
Options pricing suggests a significant move, indicating that traders are anticipating a major development.
Insulet's commitment to customer engagement could lead to higher retention rates.
Key risk
If customer growth exceeds 15%, it could challenge the current cautious sentiment in the market.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Insulet's ability to sustain growth in a competitive environment while managing operational challenges.
Bull confirmed if
Demonstrating a customer growth rate of over 15% year-over-year would confirm the bull case.
Bear confirmed if
A decline in customer growth or negative commentary on supply chain issues would confirm the bear case.
What the market is pricing for the move.
Implied Move
±21.46%
Historical Avg
±6.7%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±21.5% while PODD has averaged ±6.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
65.5%
Smart-money positioning from the most recent 13F filings.
Institutional
106.95%
of float
Insider
0.33%
of float
Holders
1,088
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
6,690,192 sh · $898.9M
9.65%
4.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Insulet beats expectations, history suggests a potential average one-day move of +1.90%, confirming strong demand and growth.
In line / cautious
If results are in line but management's commentary is cautious, the stock may experience muted movement as investors reassess their outlook.
Miss
Should Insulet miss expectations, history suggests an average one-day move of +1.09%, which could lead to further declines in stock price.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
3
1 buy·2 sells
Members
2
House + Senate
Est. Notional
$201,003.00–$515,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
4,525,333 sh · $608.0M
6.52%
-1.2%
State Street Corporation
3,197,555 sh · $429.6M
4.61%
5.1%
Vanguard Portfolio Management LLC
3,075,932 sh · $413.3M
4.44%
-10.8%
AQR Capital Management, LLC
2,455,135 sh · $329.9M
3.54%
53.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net buying
Recent Transactions
Traded Aug 18, 2026 · disclosed Sep 10, 2026
$1,001.00–$15,000.00
Traded May 7, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Traded Apr 29, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.